This book comprehensively covers the state-of-the-art and cutting-edge techlogies in an integrated fashion for applications in ADME studies of small molecular drugs. Each chapter provides descriptions of the techlogies, application scope and limitations, optimal conditions for intended results, protocols, case studies, and future developments. By concisely describing these techlogies, the book provides a useful tool for drug metabolism scientists and as a reference for scientists in the fields of pharmacology, medicinal chemistry, pharmaceutics, toxicology, bioanalytical science in academia and industry.
Donglu Zhang , PhD, is a Principal Scientist in Pharmaceutical Candidate Optimization at Bristol-Myers Squibb in Princeton, New Jersey. He has published seventy peer-reviewed articles, codiscovered the Mass Defect Filtering technique, and coedited two books. Sekhar Surapaneni , PhD, is Director, DMPK, at Celgene Corporation in New Jersey. He has published extensively in peer-reviewed journals and is a member of ISSX and ACS.
John Wiley and Sons Ltd
Date of Publication
Clinical Medicine: Professional
Place of Publication
Country of Publication
Wiley-Blackwell (an imprint of John Wiley & Sons Ltd)